Mesa Laboratories, Inc.
MLAB scores 21.5 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Net penalties of -17.4 points significantly impact the ranking. Without these adjustments, MLAB would rank considerably higher.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| MLAB | 21.5 | 138.3 | 11.5% | 1.5% | $516M |
| MPWR | 85.1 | 91.7 | 21.2% | 81.0% | $56.6B |
| ZM | 84.5 | 18.0 | 3.1% | 21.7% | $22.4B |
| NVDA | 80.7 | 45.2 | 114.2% | 55.8% | $4.6T |
| CRUS | 80.3 | 19.1 | 6.0% | 17.5% | $7.3B |
| CSCO | 78.0 | 27.6 | 5.3% | 18.0% | $311.4B |
| ASML | 77.8 | 48.1 | 15.6% | 29.4% | $566.0B |
| RMBS | 77.7 | 48.3 | 20.7% | 32.3% | $11.0B |
| IDCC | 77.7 | 31.8 | -4.0% | 48.8% | $9.6B |
| ADI | 75.6 | 74.1 | 16.9% | 20.6% | $173.8B |
| FSLR | 75.3 | 17.3 | 26.7% | 30.7% | $22.3B |
| SIMO | 74.5 | 9.2 | 10.2% | 13.8% | $4.5B |
| AAPL | 74.4 | 33.1 | 6.4% | 27.0% | $4.0T |
| DBX | 74.0 | 13.9 | 1.9% | 17.7% | $6.7B |
| LRCX | 73.9 | 48.3 | 23.7% | 29.1% | $295.9B |
| TER | 73.7 | 90.9 | 5.4% | 19.2% | $53.1B |
| Sector Average | 48.1 | 49.8 | 14.8% | -110.0% | â |
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Stock is in an uptrend above the 200-day moving average. This is the stage where institutional accumulation typically occurs. The 50-day SMA provides support.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2025 |
|---|---|---|---|---|
| Revenue | $65M | $61M | $60M | $62M |
| Gross Profit | $42M | $37M | $32M | $38M |
| Operating Income | $8M | $5M | $3M | $1M |
| Net Income | $4M | $2M | $5M | $-7M |
| EPS (Diluted) | $0.65 | $0.45 | $0.85 | $-1.31 |
| Gross Margin | 64.2% | 61.5% | 54.6% | 61.8% |
| Operating Margin | 12.2% | 7.8% | 5.1% | 2.4% |
| Net Margin | 5.6% | 4.1% | 8.0% | -11.4% |
This stock has limited trading volume and/or float. Institutional investors may face difficulty entering or exiting positions without significant price impact. A post-hoc penalty has been applied to the composite score (this is not a backtested model factor â it is a practical tradability overlay).
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2021 | $232.88 | $333.42 | 35.5% | Wide |
| 2022 | $114.21 | $332.95 | 97.8% | Wide |
| 2023 | $82.86 | $206.36 | 85.4% | Wide |
| 2024 | $83.68 | $141.17 | 51.1% | Wide |
| 2025 | $55.45 | $155.12 | 94.7% | Wide |
Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.